The Russian Federal Medical-Biological Agency (FMBA) received on Wednesday a permission for phase 2 clinical trials of the Mir-19 drug against the coronavirus, FMBA chief Veronika Skvortsova said
MOSCOW (Pakistan Point News / Sputnik - 15th April, 2021) The Russian Federal Medical-Biological Agency (FMBA) received on Wednesday a permission for phase 2 clinical trials of the Mir-19 drug against the coronavirus, FMBA chief Veronika Skvortsova said.
"We got the permit for the phase 2 clinical trials yesterday, we are fully prepared," Skvortsova told reporters on Thurdsay.
Skvortsova expressed hope that the drug would be registered by the end of the year.
Mir-19 is a unique drug based on the use of microRNAs that block certain parts of the virus.